Tripla negatív emlőrák: vizsgálatok itt: Kína
133 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleA Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 72
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07321015 - 1. fázisTaking peopleA First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
- Where
- Jinan
- Életkor
- 18 év to 75 év
- People
- 299 worldwide
- Run by
- Huahui Health
See details and how to joinNCT07623369 - No phaseTaking peopleEstablishment of a Multi-omics Prediction Model for Early Triple-negative Breast Cancer Based on UPGRADE-TNBC Study
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07773818 - 2/3. fázisCsak meghívásosPaclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer(UPGRADE-TNBC)
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06910072 - 2/3. fázisTaking peopleA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Where
- Changsha, Guangzhou
- Életkor
- 18 év to 75 év
- People
- 446
- Run by
- BeBetter Med Inc
See details and how to joinNCT07544056 - 2/3. fázisTaking peopleA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Anyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Fyzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiamen, Xiangyang, Zhengzhou
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - 2. fázisNot yet taking people in KínaRetlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
- Where
- Harbin
- Életkor
- 18 év to 100 év
- People
- 120
- Run by
- Harbin Medical University
See details and how to joinNCT07752550 - 1/2. fázisTaking peoplePaclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
- Where
- Guiyang
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Liu Shu
See details and how to joinNCT07739485 - 2. fázisTaking peopleA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 52
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06471205 - 1. fázisTaking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Beijing, Shanghai
- Életkor
- 18 év and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - No phaseTaking peopleGranzyme B-PET: Predicting Immunotherapy Efficacy in TNBC
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 30
- Run by
- Fudan University
See details and how to joinNCT07705438 - 2. fázisTaking peopleA Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- Where
- Shanghai
- Életkor
- 18 év to 80 év
- People
- 95
- Run by
- Fudan University
See details and how to joinNCT06889610 - 2. fázisTaking peoplePhase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 150
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06771609 - 2. fázisNot yet taking people in KínaA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Where
- Beijing, Harbin
- Életkor
- 18 év to 80 év
- People
- 227
- Run by
- GV20 Therapeutics
See details and how to joinNCT07623642 - 3. fázisNot yet taking people in KínaSac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 420
- Run by
- Fudan University
See details and how to joinNCT07628504 - No phaseTaking peopleA Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 59
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07622836 - 2. fázisTaking peopleSac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 24
- Run by
- Fudan University
See details and how to joinNCT07623577 - 2. fázisTaking peopleFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 716
- Run by
- Fudan University
See details and how to joinNCT05582499 - 2. fázisTaking peopleQUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 34
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07601178 - 2. fázisTaking peopleNeoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
- Where
- Nanjing
- Életkor
- 18 év to 70 év
- People
- 58
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07394387 - 2. fázisTaking peopleNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 46
- Run by
- RenJi Hospital
See details and how to joinNCT07283692 - 3. fázisNot yet taking people in KínaA Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 356
- Run by
- Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07556848 - No phaseTaking peopleReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 300
- Run by
- Fudan University
See details and how to joinNCT07551050 - 3. fázisTaking peoplePhase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Where
- Changsha, Guangzhou, Guiyang, Shanghai, Wuhan, Yichang, Yongzhou
- Életkor
- 18 év to 70 év
- People
- 246
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06889688 - 2. fázisTaking peopleFMD and Neoadjuvant Chemo-immunotherapy in TNBC
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 80
- Run by
- Sun Yat-sen University
See details and how to joinNCT07378306